Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald began coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report issued to clients and investors on Wednesday. The firm set an “overweight” rating and a $25.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 193.08% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Roth Mkm upped their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group reduced their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Maxim Group lifted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Guggenheim started coverage on Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, JMP Securities initiated coverage on Zevra Therapeutics in a research note on Tuesday, September 24th. They set an “outperform” rating and a $17.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Zevra Therapeutics currently has a consensus rating of “Buy” and an average price target of $21.57.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $8.53 on Wednesday. The stock’s fifty day simple moving average is $8.78 and its 200 day simple moving average is $7.58. The stock has a market capitalization of $455.30 million, a price-to-earnings ratio of -4.33 and a beta of 2.01. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same period in the prior year, the business posted ($0.40) EPS. As a group, sell-side analysts forecast that Zevra Therapeutics will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Large investors have recently made changes to their positions in the company. Vestal Point Capital LP acquired a new stake in Zevra Therapeutics in the third quarter valued at approximately $3,644,000. Sanctuary Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the 2nd quarter valued at $474,000. Geode Capital Management LLC boosted its holdings in Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after purchasing an additional 129,600 shares in the last quarter. Propel Bio Management LLC acquired a new position in Zevra Therapeutics during the third quarter worth $1,248,000. Finally, Simplify Asset Management Inc. bought a new position in Zevra Therapeutics during the third quarter valued at about $833,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.